Richard Thomas Menziuso, the Principal Accounting Officer at Altimmune, Inc., has reported significant transactions involving stock options and restricted stock units. This development is noteworthy as it underscores the company's strategy to align executive compensation with performance, a common practice in the pharmaceutical industry.
Background
Altimmune, Inc., a company incorporated in Delaware, operates in the pharmaceutical preparations sector. The company is known for its innovative approaches in the life sciences field. Recent filings include a Form 4 and a Form 3, both submitted on October 2, 2026, under accession number 0002156820-26-000004.
What the Filing Says
According to the filing, Menziuso reported the acquisition of 84,546 stock options at an exercise price of $2.76 on October 1, 2026. Additionally, he acquired 36,234 restricted stock units. These transactions are significant as they reflect the company’s commitment to incentivizing its executives.
Impact
This update may affect Altimmune's stakeholders, including its employees and investors, as it highlights the company's efforts to motivate its leadership team. The pharmaceutical preparations industry may also observe these transactions as they consider their own compensation frameworks.
What's Next
The filing does not say what happens next.
Vesting Schedule
The stock options and restricted stock units acquired by Menziuso are subject to specific vesting schedules. The stock options will vest over four years, with 25% of the shares becoming exercisable on October 1, 2027, followed by monthly vesting of the remaining shares over the subsequent 36 months, contingent upon Menziuso's continued service. Similarly, the restricted stock units will also vest over four years, with 25% vesting on the same date as the options, and the remainder vesting in equal annual installments for the next three years, also dependent on continued service.
Ownership Details
Following these transactions, Menziuso will directly own a total of 84,546 shares from the stock options and 36,234 shares from the restricted stock units, reflecting a significant investment in the company. This aligns his interests closely with those of shareholders, as the value of his compensation will be directly tied to the performance of Altimmune's stock.
Company Information
Altimmune, Inc. is incorporated in Delaware and operates primarily in the pharmaceutical preparations sector, classified under the Standard Industrial Classification of 2834. The company has a fiscal year ending on December 31 and is headquartered at 910 Clopper Road, Suite 201S, Gaithersburg, MD. The company’s Central Index Key (CIK) is 0001326190.
Filing Context
This Form 4 filing is part of a broader regulatory requirement under the 1934 Act, which mandates that corporate insiders disclose their transactions in the company's securities. The filing was submitted on October 2, 2026, with a reporting period ending on October 1, 2026, and is crucial for maintaining transparency with investors and the public regarding insider trading activities.